For Disclosing a new Invention to Yeda and for triggering the review process, please fill in the Preliminary Invention Disclosure Form (PIDF), attaching relevant material, if available (such as a draft article, in Word format), and send by e-mail to: firstname.lastname@example.org or by fax: (08) 9315927.
Please also send a signed original Form to the Patent Department, Yeda, via internal mail.
As you will note, the PIDF is short and contains 7 questions. Beyond the title of the invention (first question), the form includes the following questions:
a. Q 2 - Statement of inventors, who had inventive contribution to the invention (as opposed to mere labor, providing materials/samples and the sort). A patent differs from a scientific article in the sense that inventorship (unlike authorship) is determined by law. If non-inventors are listed as inventors, or if real inventors are omitted from the list of inventors, this might lead to the invalidation of the patent.
Additionally, it is important to identify non-WIS inventors, affiliated with another institution, and state their relative contribution to the invention (in percentage, Q 6). The reason for the latter being that such inventions are per definition joint to Yeda and the other institution/s. Accordingly, all patent and commercialization activities should be coordinated and agreed upon in advance between the two (or more) parties owning the invention. Such coordination is documented via an Inter-Institutional Agreement (IIA), signing of which is a pre-requisite to Yeda’s approval of the filing of a new patent application covering the joint invention. For clarifications re inventorship, kindly contact email@example.com.
b. Q 4 addresses prior public disclosures. Any such disclosure (e.g., oral presentation, abstract, poster, article) unfortunately bars the ability to file a patent application in most countries, due to novelty considerations. Hence, it diminishes considerably the commercial value of the invention. For more information re novelty, please see (link to the 5-page explanatory document).
c. Q 5 addresses funding sources. While most funding agencies are benign, or have manageable IP policies, some pose more difficult conditions (such as that IP generated with their funding is owned by the funding agency, considerable percentage of any future proceeds generated based upon said IP is to be transferred to the agency etc.). Accordingly, Yeda should be informed in advance of any funding received, as it may be crucial to the decision if to file a patent application. For more information re the policies of some common funding agencies, please see Intellectual Property Policies of Common Funding Agencies at the following link: http://www1.weizmann.ac.il/vptt/iproperty.html.
d. Q 7 addresses materials received under Material Transfer Agreement (MTA) from a third party and use of the Celera database. These have IP related clauses in the respective agreements and therefore Yeda should be made aware of them.